These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 24661041)

  • 1. Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors.
    Iyer AK; Duan Z; Amiji MM
    Mol Pharm; 2014 Aug; 11(8):2511-26. PubMed ID: 24661041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in nanoparticle-mediated siRNA delivery.
    Williford JM; Wu J; Ren Y; Archang MM; Leong KW; Mao HQ
    Annu Rev Biomed Eng; 2014 Jul; 16():347-70. PubMed ID: 24905873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of nanocarriers for the delivery of small interfering RNA.
    Kesharwani P; Gajbhiye V; Jain NK
    Biomaterials; 2012 Oct; 33(29):7138-50. PubMed ID: 22796160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyethylenimines for siRNA and miRNA delivery in vivo.
    Höbel S; Aigner A
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2013; 5(5):484-501. PubMed ID: 23720168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy.
    Du JZ; Mao CQ; Yuan YY; Yang XZ; Wang J
    Biotechnol Adv; 2014; 32(4):789-803. PubMed ID: 23933109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.
    Kuang Y; An S; Guo Y; Huang S; Shao K; Liu Y; Li J; Ma H; Jiang C
    Int J Pharm; 2013 Sep; 454(1):11-20. PubMed ID: 23867728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
    Yadav S; van Vlerken LE; Little SR; Amiji MM
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-covalent peptide-based strategy for siRNA delivery.
    Crombez L; Charnet A; Morris MC; Aldrian-Herrada G; Heitz F; Divita G
    Biochem Soc Trans; 2007 Feb; 35(Pt 1):44-6. PubMed ID: 17233597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
    Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
    Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particle carriers for combating multidrug-resistant cancer.
    Yan Y; Björnmalm M; Caruso F
    ACS Nano; 2013 Nov; 7(11):9512-7. PubMed ID: 24215340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract.
    Kriegel C; Attarwala H; Amiji M
    Adv Drug Deliv Rev; 2013 Jun; 65(6):891-901. PubMed ID: 23220324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, preparation and application of nucleic acid delivery carriers.
    Yang J; Liu H; Zhang X
    Biotechnol Adv; 2014; 32(4):804-17. PubMed ID: 24239630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
    Abbasi M; Lavasanifar A; Uludag H
    Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.
    Martirosyan A; Olesen MJ; Howard KA
    Adv Genet; 2014; 88():325-52. PubMed ID: 25409611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnology for in vivo targeted siRNA delivery.
    Dahlman JE; Kauffman KJ; Langer R; Anderson DG
    Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.